Hicon Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Sodium Iodide I-131 is not usually used for the treatment of hyperthyroidism in patients under 30 years of age unless circumstances preclude other methods of treatment.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


Therapeutic doses of Sodium Iodide I 131 Solution USP prepared with HICON® are indicated for the treatment of hyperthyroidism and selected cases of carcinoma of the thyroid.


There is currently no drug history available for this drug.

Other Information

HICON® is a kit which provides a solution of Sodium Iodide I-131 with a radioconcentration of 37 gigabecquerels/mL (1,000 millicuries/mL). Each mL of the concentrated solution contains 37 GBq of no-carrier-added Sodium Iodide I-131, < 2 mg of Disodium Edetate Dihydrate USP as a stabilizer, < 22 mg of Sodium Thiosulfate Pentahydrate USP as a reducing agent, and < 40 mg of Dibasic Sodium Phosphate Anhydrous USP. The pH of the solution is between 7.5 and 10.0.

The concentrated solution provided with HICON® is intended for use in the preparation of capsules and solution of varying strengths for oral administration for therapy.

Sodium Iodide I 131 Solution USP is designated chemically as Na 131I (MW 153.99, CAS 7790-26-3).

Hard gelatin capsules provided for the preparation of the Sodium Iodide I-131 final dosage form contain approximately 300 mg of Dibasic Sodium Phosphate Anhydrous USP as the absorbing buffer.


Iodine I-131 decays by beta emission and associated gamma emission with a physical half-life of 8.04 days.1 Photons that are useful for detection and imaging are listed in Table 1.

Table 1
Principal Radiation Emission Data

1 Kocher, David C., “Radioactive Decay Data Tables”, DOE/TIC-11026, (1981) p. 133.


 Mean % per  Disintegration

Mean Energy

Beta-4 (average)






The specific gamma-ray constant for iodine I-131 is 15.8 µCkg-1MBq-1hr-1 (2.27 R/mCi-hr) at 1 cm. The first half-value thickness of lead (Pb) for iodine I-131 is 0.24 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb is shown in Table 2. For example, the use of 2.55 cm of Pb will decrease the external radiation exposure by a factor of about 1,000.

Table 2
Radiation Attenuation by Lead Shielding

Shield Thickness
(Pb) cm

Coefficient of











To correct for physical decay of iodine I-131, the fractions that remain at selected intervals after the time of calibration are shown in Table 3.

Table 3
Physical Decay Chart: Iodine I-131 Half-Life 8.04 days

*Calibration time
Days Fraction Remaining Days Fraction Remaining Days Fraction Remaining
0* 1 11 .388 22 .151
1 .918 12 .356 23 .138
2 .842 13 .327 24 .127
3 .773 14 .300 25 .116
4 .709 15 .275 26 .107
5 .651 16 .253 27 .098
6 .597 17 .232 28 .090
7 .548 18 .213 29 .083
8 .503 19 .195 30 .076
9 .461 20 .179    
10 .423 21 .164    

Hicon Manufacturers

  • Jubilant Draximage Inc.
    Hicon (Sodium Iodide I 131) Solution [Jubilant Draximage Inc.]

Login To Your Free Account